Truist Securities Reiterates Buy Rating, $320 Price Target on Biogen (BIIB) Following Q1 Report, "Focus Remains on Lecanemab Data 3Q22"
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $320.00 price target on Biogen (NASDAQ: BIIB), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
